HK Stock Market Move | ABBISKO-B (02256) rose as much as over 6% after its self-developed highly selective CSF-1R small molecule inhibitor pimicotinib was approved for marketing in Switzerland.

ABBISKO-B (02256) rose as much as over 6%, up 3.56% as of press time at HK$6.55, with turnover of HK$15.9727 million. On the news front, recently, information on the official website of Swissmedic showed that pimicotinib, a highly selective CSF-1R small molecule inhibitor independently developed by Abbisko, has been approved for marketing in Switzerland for the treatment of adult patients with tenosynovial giant cell tumor (TGCT) that may not be suitable for surgical resection. Following its approval in China in December 2025 and in Canada in June 2026, pimicotinib has once again made progress in gaining access to overseas markets. As an oral, highly selective CSF-1R small molecule inhibitor, pimicotinib works by targeting the CSF-1/CSF-1R signaling pathway, providing a new treatment option for relevant patients. Results from the global Phase III MANEUVER study showed that at week 25, the objective response rate (ORR) assessed by the blinded independent review committee (BIRC) based on RECIST 1.1 criteria reached 54.0% in the pimicotinib group versus 3.2% in the placebo group, a difference that was statistically significant. The study also evaluated clinical benefit measures including patients' physical function and pain, providing a clinical basis for the product's global registration.